

1 *Title:* COVID-19 vaccine effectiveness against progression to in-hospital mortality — Zambia, 2021-2022

2

3 *Authors:* Duncan Chanda^{1,2*†}; Jonas Z Hines^{3*}; Megumi Itoh³; Sombo Fwoloshi^{1,2,4}; Peter A Minchella³;
4 Khozya D. Zyambo^{1,2}; Suilanji Sivile^{1,2}; Davies Kampamba²; Bob Chirwa²; Raphael Chanda¹; Katongo
5 Mutengo⁵; Mazinga F. Kayembe⁶; Webster Chewe¹; Peter Chipimo⁷; Aggrey Mweemba⁸; Simon Agolory³;
6 Lloyd B. Mulenga^{1,2}

7

8 *Affiliations:*

9 ¹University Teaching Hospital, Lusaka, Zambia

10 ²Ministry of Health, Lusaka, Zambia

11 ³U.S. Centers for Disease Control and Prevention, Lusaka, Zambia

12 ⁴University of Zambia School of Medicine, Lusaka, Zambia

13 ⁵Livingstone Teaching Hospital, Livingstone, Zambia

14 ⁶Kitwe Teaching Hospital, Kitwe, Zambia

15 ⁷Zambia National Public Health Institute, Lusaka, Zambia

16 ⁸Levy Mwanawasa University Teaching Hospital, Lusaka, Zambia

17

18 *These authors contributed equally to this report

19 †Corresponding author:

20 Duncan Chanda

21 University Teaching Hospital

22 Lusaka, Zambia

23 duncanchanda@gmail.com

24

25 *Keywords:* SARS-CoV-2; COVID-19/mortality; COVID-19 Vaccines; SARS-CoV-2; Vaccine efficacy; Zambia;

26 Africa

27

28 *Word count*

29 - Abstract: 250

30 - Article: 2,474

31

32 *Key points*

33 - Receipt of ≥ 1 COVID-19 vaccine dose reduced progression to in-hospital mortality in Zambia by

34 64.8%

35 - Mortality benefit of COVID-19 vaccines was sustained during the period of omicron transmission

36 in Zambia

37

38 **Abstract**

39 *Background:* COVID-19 vaccines are highly effective for reducing severe disease and mortality. However,
40 vaccine effectiveness data is limited from sub-Saharan Africa, where SARS-CoV-2 epidemiology has
41 differed from other regions. We report COVID-19 vaccine effectiveness against progression to in-
42 hospital mortality in Zambia.

43
44 *Methods:* We conducted a retrospective cohort study among admitted patients at eight COVID-19
45 treatment centers across Zambia during April 2021 through March 2022. Patient demographic and
46 clinical information including vaccination status and hospitalization outcome (discharged or died) were
47 collected. Multivariable logistic regression was used to assess the odds of in-hospital mortality by
48 vaccination status, adjusted for age, sex, number of comorbid conditions, disease severity, and COVID-
49 19 treatment center. Vaccine effectiveness of ≥ 1 vaccine dose was calculated from the adjusted odds
50 ratio.

51
52 *Results:* Among 1,653 patients with data on their vaccination status and hospitalization outcome, 365
53 (22.1%) died. Overall, 236 (14.3%) patients had received ≥ 1 vaccine dose before hospital admission. For
54 patients who had received ≥ 1 vaccine dose, 22 (9.3%) died compared with 343 (24.2%) among
55 unvaccinated patients ($p < 0.01$). The median time since receipt of a first vaccine dose was 52.5 days
56 (IQR: 28-107). Vaccine effectiveness for progression to in-hospital mortality among hospitalized patients
57 was 64.8% (95% CI: 42.3-79.4%).

58
59 *Conclusions:* Among patients admitted to COVID-19 treatment centers in Zambia, COVID-19 vaccination
60 was associated with lower progression to in-hospital mortality. These data are consistent with evidence

- 61 from other countries demonstrating benefit of COVID-19 vaccination against severe complications.
- 62 Vaccination is a critical tool for reducing the consequences of COVID-19 in Zambia.

63 *Introduction*

64 Since the onset of the COVID-19 pandemic, >170,000 persons have died of COVID-19 in sub-Saharan
65 Africa (1). In Zambia, from March 20, 2020 to July 13, 2022, a total of 327,570 confirmed cases and 4,009
66 confirmed deaths were recorded (2), although the true number of infections and deaths was likely
67 greater (3,4).

68
69 As of February 2022, African countries had received more than 587 million vaccine doses, enough to
70 vaccinate ~360 million people (which is ~37% doses needed to reach vaccination targets) (1). However,
71 through April 2022, only 14% of the eligible population in sub-Saharan Africa had been fully vaccinated
72 (1). The ChAdOx1-S COVID-19 vaccine became available in Zambia in April 2021 and approximately one
73 year later, ~2.3 million persons in Zambia were fully vaccinated (22% of persons aged ≥ 12 years, the
74 eligible population) (2). In addition to poor access to COVID-19 vaccines for much of 2021, several other
75 challenges hindered vaccination programs in Zambia, including sub-optimal access to preventive health
76 care/routine immunization, under-resourced health care systems, inadequate cold chain systems, lack
77 of awareness of benefits of vaccination, and vaccine misconceptions and misinformation.

78
79 COVID-19 vaccines have demonstrated excellent efficacy in clinical trials and good effectiveness in real-
80 world observational studies, including against variants of concern and in people who have had prior
81 COVID-19 infections (5-7). In particular, COVID-19 vaccines substantially reduce risk of severe disease
82 and mortality (8,9). Yet, there is paucity of vaccine efficacy and effectiveness data from countries in sub-
83 Saharan Africa. Most of the vaccine evidence from Africa have originated from South Africa, where
84 several vaccine clinical trials have been conducted and observational vaccine effectiveness (VE) studies
85 have been published (5,10-13). A single dose of the Ad26.COV2.S vaccine was associated with lower
86 hospitalizations and mortality during beta and delta waves in South Africa (11), and additional evidence

87 demonstrated effectiveness against COVID-19 hospitalizations during the omicron wave (5). In Zambia,
88 full receipt of a primary COVID-19 vaccine was associated with lower SARS-CoV-2 infections and
89 symptomatic illness during an outbreak in a prison when omicron was the dominant variant (13).
90 However, data from other countries in sub-Saharan Africa is limited to date.
91
92 Filling the COVID-19 vaccine evidence gap in Africa is important to counter misinformation and
93 skepticism toward research from other parts of the world (14,15). Furthermore, SARS-CoV-2
94 epidemiology in Africa has differed from elsewhere, with fewer confirmed cases and deaths, lower
95 symptomatic rates, yet high evidence of infection-induced immunity (16-18). Furthermore, many
96 countries in sub-Saharan Africa have a high burden of persons living with HIV (PLHIV) and tuberculosis,
97 which are conditions associated with increased risk of poor outcomes from COVID-19 (19,20). Lastly,
98 differences in social and health system structures might impact vaccine delivery. Therefore, more real-
99 world data on COVID-19 vaccines from countries in Africa are needed. We assessed COVID-19 VE against
100 progression to in-hospital mortality in patients hospitalized with COVID-19 in Zambia.

101

102 *Methodology*

103 We conducted a retrospective cohort study of patients admitted to COVID-19 treatment centers in
104 Zambia to assess COVID-19 VE against progression to in-hospital mortality between April 15, 2021 (when
105 Zambia first began offering COVID-19 vaccines) and March 31, 2022. Since the pandemic onset, patients
106 diagnosed with COVID-19 requiring in-patient admission in Zambia were admitted to COVID-19
107 treatment centers that had specifically designated isolation and treatment units staffed by clinicians and
108 nurses trained in COVID-19 clinical management (21). The COVID-19 clinical outcomes study was
109 conceived during the early weeks of the COVID-19 epidemic in Zambia and eventually included eight
110 COVID-19 treatment centers in five cities: Lusaka (four treatment centers), Ndola, Kitwe, Kabwe, and

111 Livingstone (22). Data on relative variant genome frequency by region from GISAID (Global Initiative on
112 Sharing Avian Influenza Data) were utilized to define the SARS-CoV-2 variant that was circulating during
113 each wave (23). ChAdOx1-S COVID-19 vaccine was the first vaccine type available in Zambia and by late
114 2021, Ad26.COV2.S, mRNA-127, BNT162b2 , and Sinopharm BBIBP-CorV were available in the country.
115 An additional vaccine dose after completing a primary vaccine series (i.e., “booster”) became available
116 in Zambia in January 2022. The study protocol was approved by the University of Zambia Biomedical
117 Research Ethics Committee; it was also reviewed in accordance with the US Centers for Disease Control
118 and Prevention (CDC) human research protection procedures and was determined to be research, but
119 CDC investigators did not interact with human subjects or have access to identifiable data or specimens
120 for research purposes.

121
122 Patients who provided verbal consent for clinical care at participating treatment centers had
123 demographic and clinical data collected at admission and during hospitalization until they were
124 discharged or died. Data were retrospectively abstracted from clinical records using a standardized case
125 record form adapted from WHO (24) and entered into REDCap (Research Electronic Data Capture)
126 electronic data capture tools by trained staff at a later date (25). Vaccination information was collected
127 from patients during clinical care and recorded in their charts. Proof of vaccination included self-report
128 and/or review of vaccine card. For those with missing vaccine information, attempts were made to
129 cross-reference the electronic national vaccine registry to improve data completeness. Severe COVID-19
130 was defined as having an oxygen saturation (SpO₂) <90%, respiratory rate >30 breaths/minute, or need
131 for oxygen therapy (26). The number of self-reported comorbidities was summed for each patient,
132 including cardiac disease, hypertension, diabetes, other pulmonary disease, HIV, tuberculosis (active or
133 previous), asthma, kidney disease, liver disease, neurological disorders, asplenia, malignant neoplasms,

134 and current smoking. History of prior COVID-19 was not available for patients, although the reliability of
135 this history is not clear given a low case detection proportion in Zambia (3).

136

137 Full vaccination was defined as receiving the 1st dose of a one-dose vaccine or 2nd dose of a two-dose
138 vaccine ≥ 14 days prior to COVID-19 treatment center admission. Partial vaccination was defined as
139 receiving the 1st dose of a two-dose vaccine ≥ 14 days prior to admission but either not yet receiving the
140 2nd dose or receiving the 2nd dose ≤ 13 days prior to admission. Those vaccinated with their 1st COVID-
141 19 vaccine dose ≤ 13 days prior to admission were considered indeterminate and those with missing
142 vaccine dates were classified as such. Because vaccination dates were missing for many patients with
143 known vaccination status, we also created a separate category of patients who received ≥ 1 COVID-19
144 vaccine dose and used this as our primary predictor variable (with full/partial vaccination status being
145 secondary analyses). The main outcome variable was categorized as discharged from hospital or died in
146 the hospital. Length of stay was calculated as the days between admission and discharge or death.
147 Patients whose vaccination status or hospitalization outcomes could not be determined were excluded
148 from the analyses.

149

150 The analysis was restricted to patients admitted during the period that COVID-19 vaccines were
151 available in Zambia (April 15, 2021, through March 31, 2022). We used chi-square test and student's t-
152 test to compare categorical and continuous variables, respectively. We used multivariable logistic
153 regression to calculate the odds of in-hospital mortality by vaccination status, adjusting for age, sex,
154 number of comorbid conditions, disease severity at admission, hospitalization month, and COVID-19
155 treatment center. VE was calculated as 1 minus the adjusted odds ratio times 100. We did secondary
156 analyses to calculate VE by full/partial vaccination status, vaccine type, the predominant circulating
157 variant (i.e., delta from April to November 2021, and omicron [subvariants B1 and B2 (23)] from

158 December 2021 through March 2022 (27)), and HIV status. Additionally, we analyzed if there was an
159 association between progression to in-hospital mortality and predominant variant periods (delta versus
160 omicron waves), adjusting for patients' vaccination status.

161

162

163 *Results*

164 Overall, 2,385 persons had data on their hospitalization course abstracted at a COVID-19 treatment
165 center in Zambia during April 2021 through March 2022. Of patients with data abstracted, 1,821 (76.4%)
166 had vaccination status documented (815 [61.5%] persons during the delta variant predominant period
167 and 1,006 [94.9%] persons during the omicron variant predominant period). Among patients with
168 known vaccination status, 1,653 (69.3% of total) had a known hospitalization outcome (Figure 1).

169

170 The median age of participants was 47 years (interquartile range [IQR]: 30-65 years) and females
171 accounted for 852 (51.5%) patients (Table 1). Overall, 1,065 (64.4%) patients reported having at least
172 one comorbidity, with 266 (17.9%) patients reporting having HIV infection (compared to national
173 prevalence of 11.1% in persons aged 15-49 years (28)). The average length of stay was 2.5 days and 365
174 (22.1%) patients died during their hospitalization.

175

176 Two-hundred thirty-six (14.3%) patients had received ≥ 1 vaccine dose before hospital admission, of
177 whom 55 (23.3%) were fully vaccinated, 30 (12.7%) were partially vaccinated, 8 (3.4%) had an
178 indeterminate vaccination status, and 143 (60.6%) were missing information on vaccination date(s)
179 (Table 1). No patient had a record of receiving a 3rd vaccine dose. The median time since receipt of a first
180 vaccine dose was 52.5 days (IQR: 28-107).

181

182 The average length of stay for patients with ≥ 1 vaccine dose was 1.9 days versus 2.6 days for
183 unvaccinated patients ($p < 0.01$,) (Table 1). Twenty-two (9.3%) patients reporting ≥ 1 vaccine dose died
184 compared to 343 (24.2%) unvaccinated patients ($p < 0.01$). VE of ≥ 1 COVID-19 vaccine dose against
185 progression to in-hospital mortality was 64.8% (95% confidence interval [CI]: 42.3-79.4) (Table 2). VE of
186 ≥ 1 vaccine dose during the period when delta was dominant was 65.0% (95% CI: 22.5-85.8) and during
187 the period when omicron was dominant was 64.8% (95% CI: 31.4-82.9).

188
189 Among the 266 patients with HIV, 5 (14.3%) who had received ≥ 1 COVID-19 vaccine dose died compared
190 to 61 (26.4%) who were unvaccinated ($p = 0.18$). VE of ≥ 1 COVID-19 vaccine dose against progression to
191 in-hospital mortality among PLHIV was 53.6% (-15.6-84.7).

192
193 In-hospital mortality among patients in the study was higher during the delta variant predominant
194 period than the omicron variant predominant period (31.1% vs. 14.5%; $p < 0.01$; odds ratio: 2.7 [95% CI:
195 2.1-3.4]) (Table 3). Adjusting for the different vaccination coverage of patients between waves (6.1%
196 during delta versus 21.1% during omicron) did not appreciably change the odds of in-hospital mortality
197 (adjusted odds ratio: 2.4 [95% CI: 1.9-3.1]).

198
199 *Discussion*

200 Patients vaccinated against COVID-19 had lower progression to in-hospital mortality in Zambia, a finding
201 that was consistent during periods when delta and omicron were the dominant variants circulating in
202 the country. These data from Zambia expand on limited evidence of COVID-19 VE in Africa (5,10-13).
203 COVID-19 vaccination uptake in Africa has lagged other regions but evidence suggests that they are a
204 critical tool for reducing morbidity and mortality from COVID-19. Sharing local evidence of the benefit of
205 COVID-19 vaccine in Zambia might increase vaccine uptake.

206
207 Omicron variant of SARS-CoV-2 has mutations that enable it to evade prior immunity, resulting in
208 decreased VE (6). However, protection from severe COVID-19 outcomes is the most conserved vaccine
209 effect across different variants, especially following a booster dose (9,29,30). In our study, there was no
210 decrement in VE against progression to in-hospital mortality when omicron was the predominant variant
211 in Zambia (compared to when delta was predominant). Patients in this analysis had been vaccinated
212 relatively recent (i.e., less than two months), which could explain preserved VE (6); additionally, data
213 from before the omicron surge in the U.S. indicate preserved VE against hospitalization of a single dose
214 adenovirus vaccine for at least six months (31,32).

215
216 Even though VE remained similar between the delta and omicron waves in this study, the in-hospital
217 mortality risk was lower during the omicron wave. However, this mortality difference was not driven by
218 higher vaccination coverage among patients during the omicron wave. This finding is similar to those in
219 a study by Modes et al. demonstrating that in one U.S. hospital, fewer fully vaccinated patients died in-
220 hospital during the omicron wave compared to the delta wave (33). This suggests other factors like
221 patient characteristics (e.g., greater proportion of patients with infection-induced immunity during the
222 omicron wave, higher risk patients admitted during the delta wave), system/environmental factors (e.g.,
223 relative availability of hospital beds or oxygen supply in Zambia, which were much more constrained
224 during the delta wave than during the omicron wave), and/or virus characteristics (e.g., omicron lower
225 replication competence in lung parenchyma (34)) could be responsible for the mortality difference by
226 wave in Zambia (20).

227
228 Some clinical trials for COVID-19 vaccines included PLHIV, although the numbers were too small to
229 derive definitive evidence of efficacy in PLHIV (12,35). Based on immunological studies, vaccines are

230 expected to work well in this high-risk population (36). The Ad26.COVID.S vaccine has been
231 demonstrated to reduce hospitalizations and deaths among PLHIV in South Africa (11), and in Russia, the
232 Gam-COVID-VAC vaccine was shown to be effective in PLHIV, especially for severe disease (37).
233 Although COVID-19 vaccination among PLHIV appeared to be effective against progression to in-hospital
234 mortality in this study, the effect was not statistically significant. The inclusion of additional PLHIV in this
235 study could provide a clearer evidence on this important topic in Zambia, where there is a high burden
236 of HIV (28).

237
238 Vaccinated patients in this study were also less likely than unvaccinated patients to be admitted to
239 treatment centers with severe COVID-19, suggesting that vaccination also helped prevent this outcome.
240 Although vaccine coverage in this study was low, it varied by geographic location, suggesting
241 opportunities to learn from best practices in some areas to help other areas increase vaccine coverage.

242
243 Our study had several limitations. Data were not available describing either national COVID-19-related
244 hospitalization numbers or COVID-19 hospitalization rates by facility, limiting our understanding of the
245 study's generalizability. As with many studies conducted during emergency responses, data
246 completeness for some key variables was a challenge that impacted our sample size and resulted in
247 wide confidence intervals. Additionally, the lack of vaccination dose numbers and dates for many
248 participants necessitate use of a non-standard category (i.e., ≥ 1 vaccine dose) for the primary analysis to
249 avoid excessive loss of participants; the similarity of VE estimates for full and missing vaccination
250 statuses could indicate that many patients with missing vaccination status were in fact fully vaccinated.
251 Additionally, given high levels of infection-induced immunity in Africa (16), hybrid immunity likely
252 confers substantial protection against severe consequence of COVID-19 in Zambia (38). Variant periods
253 were defined based on predominant variants in GISAID data in Zambia and not on sequencing results

254 from patients in the study. HIV status was self-reported, which could have led to biased VE findings in
255 PLHIV. Lastly, there are potentially other unaccounted for confounders which couldn't be factored into
256 the VE analysis.

257
258 Vaccination is a critical tool to reduce the consequences of the SARS-CoV-2 epidemic. These findings are
259 among the first from countries in Africa, and such real-world evidence of COVID-19 vaccines could help
260 increase vaccination in a region that lags the rest of the world by providing local evidence of vaccine
261 benefits in preventing COVID-19 mortality. Substantially increasing COVID-19 vaccinations will help
262 Zambia reach targets and reduce COVID-19 mortality in the country.

263
264
265 *Acknowledgements:* Lydia Chama (University Teaching Hospital, Lusaka); Martha Ilunga (Kawama Health
266 Center, Kabwe); Florence Chanda Miti (Levy Mwanawasa University Teaching Hospital, Lusaka); Evelyn
267 Mwamba (University Teaching Hospital, Lusaka); Naomi Charity Mwananyau (Levy Mwanawasa
268 University Teaching Hospital, Lusaka); Francis D. Mwansa (Ministry of Health, Lusaka); Linda Musonda
269 (University Teaching Hospital, Lusaka); Agness Mutaja (National Heart Hospital, Lusaka); Charles
270 Mutemba (University Teaching Hospital, Lusaka); Prosperllina Ndhlovu (Ndola Teaching Hospital, Ndola);
271 Amideos Nshikita (Maina Soko Medical Centre, Lusaka); Christabel Phiri (Levy Mwanawasa University
272 Teaching Hospital, Lusaka); Constance Phiri (University Teaching Hospital, Lusaka); Miracle Phiri (Levy
273 Mwanawasa University Teaching Hospital, Lusaka); Mary M. Siamupa (Livingstone Central Hospital,
274 Livingstone); Vanessa Tayali (Kabwe Central Hospital, Kabwe); Harriet Nandi Zulu (Ndola Teaching
275 Hospital, Ndola);

276

277

278

279 *Attribution of Support:* This work has been supported by the Zambia Ministry of Health and the U.S.

280 President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and

281 Prevention (CDC) and the CDC Emergency Response to the COVID-19 pandemic.

282

283 *Authorship Disclaimer:* The findings and conclusions in this report are those of the author(s) and do not

284 necessarily represent the official position of the funding agencies.

285

286

287

288

289 *References*

- 290 1. World Health Organization Regional Office for Africa (WHO AFRO). COVID-19 vaccination in the
291 WHO African region; Monthly bulletin [Internet]. Brazzaville, Congo; Available from:
292 <https://apps.who.int/iris/bitstream/handle/10665/354270/CV-20220513-eng.pdf>
- 293 2. Zambia National Public Health Institute. Zambia COVID-19 Statistics; Daily Status Update
294 [Internet]. Available from: <https://www.facebook.com/ZMPublicHealth/>
- 295 3. Mulenga LB, Hines JZ, Fwoloshi S, Chirwa L, Siwingwa M, Yingst S, et al. Prevalence of SARS-CoV-2
296 in six districts in Zambia in July, 2020: a cross-sectional cluster sample survey. *Lancet Glob Heal*
297 [Internet]. 2021;9(6):e773–81. Available from: [http://dx.doi.org/10.1016/S2214-109X\(21\)00053-](http://dx.doi.org/10.1016/S2214-109X(21)00053-X)
298 X
- 299 4. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-
300 related mortality, 2020-21. *Lancet (London, England)*. 2022 Apr;399(10334):1513–36.
- 301 5. Collie S, Champion J, Moultrie H, Bekker L-G, Gray G. Effectiveness of BNT162b2 Vaccine against
302 Omicron Variant in South Africa. Vol. 386, *The New England journal of medicine*. 2022. p. 494–6.
- 303 6. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 Vaccine
304 Effectiveness against the Omicron (B.1.1.529) Variant. *N Engl J Med*. 2022 Apr;386(16):1532–46.
- 305 7. Plumb ID, Feldstein LR, Barkley E, Posner AB, Bregman HS, Hagen MB, et al. Effectiveness of
306 COVID-19 mRNA Vaccination in Preventing COVID-19-Associated Hospitalization Among Adults
307 with Previous SARS-CoV-2 Infection - United States, June 2021-February 2022. *MMWR Morb*
308 *Mortal Wkly Rep*. 2022 Apr;71(15):549–55.
- 309 8. Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real-world effectiveness of COVID-19
310 vaccines: a literature review and meta-analysis. *Int J Infect Dis*. 2022 Jan;114:252–60.

- 311 9. Tenforde MW, Self WH, Gaglani M, Ginde AA, Douin DJ, Talbot HK, et al. Effectiveness of mRNA
312 Vaccination in Preventing COVID-19-Associated Invasive Mechanical Ventilation and Death -
313 United States, March 2021-January 2022. *MMWR Morb Mortal Wkly Rep.* 2022 Mar;71(12):459–
314 65.
- 315 10. Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, et al. Efficacy of the ChAdOx1 nCoV-
316 19 Covid-19 Vaccine against the B.1.351 Variant. *N Engl J Med.* 2021;
- 317 11. Bekker L-G, Garrett N, Goga A, Fairall L, Reddy T, Yende-Zuma N, et al. Effectiveness of the
318 Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a
319 single-arm, open-label, phase 3B, implementation study. *Lancet (London, England).* 2022
320 Mar;399(10330):1141–53.
- 321 12. Vaccines and Related Biological Products Advisory Committee Meeting February 26, 2021. In:
322 FDA Briefing Document; Janssen Ad26COV2S Vaccine for the Prevention of COVID-19 [Internet].
323 Available from: <https://www.fda.gov/media/146217/download>
- 324 13. Simwanza J, Hines JZ, Sinyange D, Sinyange N, Mulenga C, Hanyinza S, et al. COVID-19 vaccine
325 effectiveness during a prison outbreak when the Omicron was the dominant circulating variant—
326 Zambia, December 2021. *medRxiv [Internet].* 2022; Available from:
327 <https://www.medrxiv.org/content/10.1101/2022.05.06.22274701v1>
- 328 14. Menezes NP, Simuzingili M, Debebe ZY, Pivodic F, Massiah E. What is driving COVID-19 vaccine
329 hesitancy in Sub-Saharan Africa? [Internet]. *World Bank Blogs.* [cited 2022 Jun 27]. Available
330 from: [https://blogs.worldbank.org/africacan/what-driving-covid-19-vaccine-hesitancy-sub-](https://blogs.worldbank.org/africacan/what-driving-covid-19-vaccine-hesitancy-sub-saharan-africa)
331 [saharan-africa](https://blogs.worldbank.org/africacan/what-driving-covid-19-vaccine-hesitancy-sub-saharan-africa)
- 332 15. Africa Centres for Disease Control. COVID 19 Vaccine Perceptions: A 15 country study [Internet].


- 333 Addis Ababa, Ethiopia; Available from: <https://africacdc.org/download/covid-19-vaccine->
334 [perceptions-a-15-country-study/](https://africacdc.org/download/covid-19-vaccine-perceptions-a-15-country-study/)
- 335 16. Lewis H, Al E. SARS-CoV-2 infection in Africa: A systematic review and meta-analysis of
336 standardised seroprevalence studies, from January 2020 to December 2021. medRxiv [Internet].
337 Available from: www.medrxiv.org/content/10.1101/2022.02.14.22270934v1
- 338 17. Salyer SJ, Maeda J, Sembuche S, Kebede Y, Tshangela A, Moussif M, et al. The first and second
339 waves of the COVID-19 pandemic in Africa: a cross-sectional study. Lancet [Internet].
340 2021;397(10281):1265–75. Available from: [http://dx.doi.org/10.1016/S0140-6736\(21\)00632-2](http://dx.doi.org/10.1016/S0140-6736(21)00632-2)
- 341 18. Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, et al. Coronavirus
342 Pandemic (COVID-19) [Internet]. Available from: <https://ourworldindata.org/coronavirus>
- 343 19. Jassat W, Cohen C, Tempia S, Masha M, Goldstein S, Kufa T, et al. Risk factors for COVID-19-
344 related in-hospital mortality in a high HIV and tuberculosis prevalence setting in South Africa: a
345 cohort study. Lancet HIV. 2021;3018(21):1–14.
- 346 20. Minchella P, Chanda D, Hines J, Fwoloshi S, Itoh M, Kampamba D, et al. The first four COVID-19
347 waves in Zambia: Comparison of epidemiologic and clinical characteristics among persons
348 hospitalized for COVID-19. Pending Publ. 2022;
- 349 21. World Health Organization. COVID-19 Case Definition [Internet]. 2020. Available from:
350 https://www.who.int/publications/i/item/WHO-2019-nCoV-Surveillance_Case_Definition-2020.2
- 351 22. Chanda D, Minchella PA, Kampamba D, Itoh M, Hines JZ, Fwoloshi S, et al. COVID-19 Severity and
352 COVID-19–Associated Deaths Among Hospitalized Patients with HIV Infection — Zambia, March–
353 December 2020. MMWR Morb Mortal Wkly Rep. 2021;70(22):807–10.
- 354 23. GISAID - EpiCov [Internet]. [cited 2022 Feb 18]. Available from:

- 355 <https://www.epicov.org/epi3/frontend#220b8c>
- 356 24. World Health Organization (WHO). The WHO Global Clinical Platform for COVID-19 [Internet].
357 2020. Available from: [https://www.who.int/teams/health-care-readiness-clinical-unit/covid-](https://www.who.int/teams/health-care-readiness-clinical-unit/covid-19/data-platform)
358 [19/data-platform](https://www.who.int/teams/health-care-readiness-clinical-unit/covid-19/data-platform).
- 359 25. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, et al. The REDCap consortium:
360 Building an international community of software platform partners. J Biomed Inform. 2019
361 Jul;95:103208.
- 362 26. World Health Organization. COVID-19 Clinical Management; Living Guidance [Internet]. 2021.
363 Available from: <https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1>
- 364 27. Mwenda-Chimfwembe M, Saasa N, Bridges D. Genomic epidemiology of novel coronavirus -
365 Africa_Zambia-focused subsampling [Internet]. [cited 2022 Feb 16]. Available from:
366 <https://nextstrain.org/groups/SC2ZamPub/ncov/africa/zambia>
- 367 28. UNAIDS. AIDSinfo | UNAIDS [Internet]. People living with HIV (all ages). Available from:
368 <http://aidsinfo.unaids.org/>
- 369 29. Thompson MG, Natarajan K, Irving SA. Effectiveness of a Third Dose of mRNA Vaccines Against
370 COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations
371 Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10
372 States, August 2021–. Morb Mortal Wkly Rep [Internet]. ePub: 21 J. Available from:
373 [https://www.cdc.gov/mmwr/volumes/71/wr/mm7104e3.htm?s_cid=mm7104e3_x#suggestedcit](https://www.cdc.gov/mmwr/volumes/71/wr/mm7104e3.htm?s_cid=mm7104e3_x#suggestedcitation)
374 [ation](https://www.cdc.gov/mmwr/volumes/71/wr/mm7104e3.htm?s_cid=mm7104e3_x#suggestedcitation)
- 375 30. Lin D-Y, Gu Y, Wheeler B, Young H, Holloway S, Sunny S-K, et al. Effectiveness of Covid-19
376 Vaccines over a 9-Month Period in North Carolina. N Engl J Med. 2022 Jan;

- 377 31. Polinski JM, Weckstein AR, Batech M, Kabelac C, Kamath T, Harvey R, et al. Durability of the
378 Single-Dose Ad26.COV2.S Vaccine in the Prevention of COVID-19 Infections and Hospitalizations
379 in the US Before and During the Delta Variant Surge. *JAMA Netw open*. 2022 Mar;5(3):e222959.
- 380 32. Lewis NM, Self WH, Gaglani M, Ginde AA, Douin DJ, Keipp Talbot H, et al. Effectiveness of the
381 Ad26.COV2.S (Johnson & Johnson) COVID-19 Vaccine for Preventing COVID-19 Hospitalizations
382 and Progression to High Disease Severity in the United States. *Clin Infect Dis an Off Publ Infect*
383 *Dis Soc Am*. 2022 Jun;
- 384 33. Modes ME, Directo MP, Melgar M, Johnson LR, Yang H, Chaudhary P, et al. Clinical Characteristics
385 and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection
386 During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One
387 Hospital, California, July 15-September 23, 2021, and De. *MMWR Morb Mortal Wkly Rep*. 2022
388 Feb;71(6):217–23.
- 389 34. Hui KPY, Ho JCW, Cheung M-C, Ng K-C, Ching RHH, Lai K-L, et al. SARS-CoV-2 Omicron variant
390 replication in human bronchus and lung ex vivo. *Nature*. 2022 Mar;603(7902):715–20.
- 391 35. Shinde V, Bhikha S, Hoosain Z, Archary M, Borat Q, Fairlie L, et al. Efficacy of NVX-CoV2373
392 Covid-19 Vaccine against the B.1.351 Variant. *N Engl J Med*. 2021;384(20).
- 393 36. Alcorn K. COVID-19 vaccines in people with HIV [Internet]. *aidsmap*. [cited 2022 Apr 26].
394 Available from: <https://www.aidsmap.com/about-hiv/covid-19-vaccines-people-hiv>
- 395 37. Gushchin VA, Tsyganova E V, Ogarkova DA, Adgamov RR, Shcheblyakov D V, Glukhoedova N V, et
396 al. Sputnik V protection from COVID-19 in people living with HIV under antiretroviral therapy.
397 *EClinicalMedicine*. 2022 Apr;46:101360.
- 398 38. World Health Organization. Strategic Advisory Group of Experts (SAGE) on Immunization: Interim

399 statement on hybrid immunity and increasing population seroprevalence rates [Internet]. [cited
400 2022 Jun 27]. Available from: [https://www.who.int/news/item/01-06-2022-interim-statement-](https://www.who.int/news/item/01-06-2022-interim-statement-on-hybrid-immunity-and-increasing-population-seroprevalence-rates)
401 [on-hybrid-immunity-and-increasing-population-seroprevalence-rates](https://www.who.int/news/item/01-06-2022-interim-statement-on-hybrid-immunity-and-increasing-population-seroprevalence-rates)
402

403 Figure 1. Sample size flow diagram for analysis of COVID-19 vaccine effectiveness against in-hospital
404 mortality in Zambia, 2021-2022



405

406 Table 1. Characteristics and outcomes of patients admitted to COVID-19 treatment centers with known
 407 hospitalization outcome in Zambia, 2021-2022

Characteristic	Overall (N = 1,653)	Vaccinated (n = 236)	Unvaccinated (n = 1,417)	p-value*
Age, median (IQR) (n miss = 3)	47 (30-65)	42 (29-61)	48 (30-66)	0.10
Age group, n (%) (n miss = 3)				
0-17	78 (4.7)	4 (1.7)	74 (5.2)	0.02
18-29	322 (19.5)	57 (24.3)	265 (18.7)	
30-44	370 (22.4)	60 (25.5)	310 (21.9)	
45-59	331 (20.1)	48 (20.4)	283 (20.0)	
≥60	549 (33.3)	66 (28.1)	483 (34.1)	
Sex, n (%)				
Female	852 (51.5)	133 (56.4)	719 (50.7)	0.13
Male	801 (48.5)	103 (43.6)	698 (49.3)	
District, n (%) (n miss = 48)				
Lusaka	715 (44.5)	99 (42.3)	616 (44.9)	<0.01
Ndola	426 (26.5)	36 (15.4)	390 (28.4)	
Kitwe	209 (13.0)	75 (32.1)	134 (9.8)	
Livingstone	139 (8.7)	15 (6.4)	124 (9.0)	
Kabwe	116 (7.2)	9 (3.8)	107 (7.8)	

Comorbidity number, n (%)*				
0	588 (35.6)	81 (34.3)	507 (35.8)	0.93
1	535 (32.3)	77 (32.6)	458 (32.3)	
2	326 (19.7)	46 (19.5)	280 (19.8)	
≥3	204 (12.3)	32 (13.6)	172 (12.1)	
Comorbidities, n (%) [†]				
Hypertension (n miss = 78)	564 (35.8)	79 (35.4)	485 (35.9)	0.96
HIV (n miss = 159)	266 (17.9)	35 (15.5)	231 (18.4)	0.35
Diabetes (n miss = 114)	222 (14.4)	41 (19.0)	181 (13.7)	0.05
Severe COVID-19 at admission, n				
	872 (53.1)	83 (35.3)	789 (56.1)	<0.01
(%) [‡] (n miss = 12)				
Mean length of stay, days (range)				
	2.5 (0-27)	1.9 (0-27)	2.6 (0-27)	<0.01
Hospitalized ≥5 days, n (%)				
	287 (17.4)	29 (12.3)	258 (18.2)	0.03
Died during hospitalization, n (%)				
	365 (22.1)	22 (9.3)	343 (24.2)	<0.01
Timing of 1 st vaccine dose, n (%)				
≥14 days before admission	-	85 (36.0)	-	-
0-13 days before admission	-	8 (3.4)	-	-
After admission	-	0 (0.0)	-	-
Missing date	-	143 (60.6)	-	-
Vaccination status, n (%) [¶]				
Fully	-	55 (23.3)	-	-

Partially	-	30 (12.7)	-	-
Indeterminate	-	8 (3.4)	-	-
Missing date		143 (60.6)		
Median time since vaccination, days (IQR) (n miss: 146)**		52.5 (28-107)	-	-
Vaccine type, n (%) (n miss = 27)				
Ad26.COV2.S	-	121 (57.9)	-	-
ChAdOx1-S	-	84 (40.2)	-	-
BNT162b2	-	3 (1.4)	-	-
mRNA-127	-	1 (0.5)	-	-
Sinopharm BBIBP-CorV	-	0 (0.0)	-	-

* Chi-square test used for categorical variables and student t-test used for continuous variables

[†] Comorbidities included cardiac disease, hypertension, diabetes, other pulmonary disease, HIV, tuberculosis (active or previous), asthma, kidney disease, liver disease, neurological disorder, asplenia, malignant neoplasm, and current smoking. Only the most common comorbidity options are shown in the table. [‡] Severe COVID-19 was defined as an oxygen saturation <90% on room air, respiratory rate >30 breaths per minute, or receiving oxygen therapy

[¶] Full vaccination defined as receiving the 1st dose of a one-dose vaccine or 2nd dose of a two-dose vaccine ≥14 days prior to COVID-19 treatment center admission, partial vaccination defined as receiving the 1st dose of a two-dose vaccine ≥14 days prior to admission but either not yet receiving the 2nd dose or receiving the 2nd dose ≤13 days prior to admission, and indeterminate vaccination status defined as receiving the 1st COVID-19 vaccine dose ≤13 days prior to admission

** 146 missing date since first dose received. Three of these persons had date of second dose, meaning they could be classified as fully vaccinated in prior analyses

IQR: interquartile range

408

409

410 Table 2. COVID-19 vaccine effectiveness against progression to in-hospital mortality - Zambia, April 2021-March 2022

Vaccination status	Deaths in vaccinated group*, n (%)	Vaccine effectiveness, % (95% CI)	
		Crude VE	Adjusted VE [†]
≥1 vaccine dose (n = 236)	22 (9.3)	67.8 (50.4-80.1)	64.8 (42.3-79.4)
Vaccination status [‡]			
Full (n = 55)	6 (10.9)	61.7 (16.5-85.4)	60.9 (2.3-86.5)
Partial (n = 30)	4 (13.3)	51.8 (-24.7-85.9)	61.3 (-15.8-89.7)
Indeterminate (n = 8)	0 (0.0)	-	-
Missing (n = 143)	12 (8.4)	71.3 (49.7-85.1)	63.4 (29.7-82.3)
Time period (predominant variant) ^{¶, **}			
April to November 2021 (delta) (n = 46)	8 (17.4)	55.3 (7.5-80.9)	65.0 (22.5-85.8)
December 2021 to March 2022 (omicron) (n = 190)	14 (7.4)	59.6 (30.2-78.3)	64.8 (31.4-82.9)
Vaccine type [¶]			
ChAdOx1-S (n = 84)	9 (10.7)	62.1 (32.9-80.5)	65.2 (33.5-83.1)

Ad26.COV2.S (n = 121)	10 (8.3)	69.9 (48.2-84.0)	61.1 (26.6-80.8)
-----------------------	----------	------------------	------------------

* 343 (24.2%) patients died in the unvaccinated group (n = 1,417)

[†] Adjusted for age, sex, number of comorbid conditions, disease severity at admission (defined as oxygen saturation <90% on room air, respiratory rate >30 breaths per minute, or receiving oxygen therapy), hospitalization month, and COVID-19 treatment center

[‡] Full vaccination defined as receiving the 1st dose of a one-dose vaccine or 2nd dose of a two-dose vaccine ≥14 days prior to COVID-19 treatment center admission, partial vaccination defined as receiving the 1st dose of a two-dose vaccine ≥14 days prior to admission but either not yet receiving the 2nd dose or receiving the 2nd dose ≤13 days prior to admission, and indeterminate vaccination status defined as receiving the 1st COVID-19 vaccine dose ≤13 days prior to admission

[¶] Estimate for receipt of ≥1 COVID-19 vaccine dose

** In the delta variant predominant period, there were 706 unvaccinated patients, of whom 226 (32.0%) died during hospitalization. In the omicron variant predominant period, there were 711 unvaccinated patients, of whom 117 (16.5%) died during hospitalization.

CI: confidence interval; VE: vaccine effectiveness

411

412

413 Table 3. In-hospital mortality by COVID-19 pandemic period (proxy for predominant variant) and vaccination status — Zambia, 2021-2022

Outcome	All patients, n (%)			Unvaccinated, n (%)			≥1 vaccine dose, n (%)		
	Delta	Omicron	p-value*	Delta	Omicron	p-value*	Delta	Omicron	p-value*
	period (n = 752)	period (n = 901)		period (n = 706)	period (n = 711)		period (n = 46)	period (n = 190)	
Severe illness at admission	552 (73.4)	320 (35.5)	<0.01	517 (73.2)	272 (38.3)	<0.01	35 (76.1)	48 (25.3)	<0.01
In-hospital mortality	234 (31.1)	131 (14.5)	<0.01	226 (32.0)	117 (16.5)	<0.01	8 (17.4)	14 (7.4)	0.05

Delta period defined as April to November 2021 and Omicron period defined as December 2021 through March 2022

* Chi-square test or Fischer exact test where appropriate

414

415